Incorporating Straticyte™ Could Enhance Assessment of Cancer Risk in Oral Lesions

MaRS Discovery District, Toronto, ON; December 14, 2020 – Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that Oral Cancer and the Race Against Time: Use of Psoriasin (S100A7) as a Predictive Marker to Enhance Assessment of Cancer Risk in Oral Lesions published today in Oral Health, recognizes that the addition of prognostic biomarkers (like S100A7) to the diagnostic toolkit could ultimately guide clinicians to a more confident and supported treatment plan, favouring early detection and preventive action.

Dr. Mark Darling, professor in Pathology at Western University (London, ON) and the senior author of the article says: “Future implementation of Straticyte™ into the clinical risk assessment of suspicious oral lesions could be used to complement current methods of traditional dysplasia grading. The combined evaluation of multiple preneoplastic components (including Straticyte) could provide a more holistic, objective, and assured assessment of oral cancer risk, to better guide treatment. Incorporation of prognostic biomarker tests, like Straticyte, is on the imminent horizon, with great potential to heighten early cancer detection and improve patient outcomes.”

The article can be viewed here.

About Proteocyte

Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Center, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.